Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Illinois Counties Facing Increases In STDs Among Teenagers; Bill Aims To Reduce Rates
Illinois health officials contend that images seen in the media, social influences, and a lack of "frank" discussion on STDs in schools, among other issues, might be contributing to increases in STD rates across the state, the State Journal-Register reports. "According to recently released data, new cases of chlamydia in Illinois reached an all-time high statewide in 2008 - 59,169 - while the number of gonorrhea cases outside Chicago has been rising in recent years and totaled 10,165 in 2008," the Journal-Register reports. In addition, about 35,000 state residents have HIV/AIDS, the article states. Charlie Rabins, chief of the STD program at the Illinois Department of Public Health, said a bill (SB 212) currently awaiting Gov. Pat Quinn"s (D) approval might help reduce STD rates. The bill "would allow what is called "expedited partner therapy," in which medical professionals who treat patients for gonorrhea or chlamydia can give those patients single-dose antibiotics to pass on to sexual partners without first examining the partners," according to the Journal-Register (Olsen, 7/27).
generic viagra online
Kennedy Plan Skips Contentious Issues, Still Angers GOP
The first detailed health reform proposal "got off to a rocky start Tuesday," as "even moderate Republicans" attacked a draft bill by Sen. Edward Kennedy, D-Mass., and Democrats from his Health, Education, Labor and Pensions Committee, the Los Angeles Times reports. Many of the proposals goals are "broadly shared by lawmakers of both parties," but GOP legislators complained they were excluded from the drafting process and that the Democrats are rushing reform.
News of the day
Fees Announced By Society's Council, UK
The Council of the Royal Pharmaceutical Society of Great Britain has announced a fee
Medical Devices

Biovail Receives 2009 Corporate Award From National Organization For Rare Disorders

Biovail Corporation (NYSE: BVF)(TSX: BVF) announced that the Company has received the 2009 Corporate Award from the National Organization for Rare Disorders (NORD) for the development of Xenazine® for the treatment of chorea in association with Huntington"s disease. The Award was presented last night at NORD"s Partners in Progress Gala in Washington D.C. In accepting the award, Dr. Robert Ashworth, Biovail"s Vice-President, Regulatory Affairs said, "This award to Biovail represents the culmination of a collaborative effort among investigators, patient advocacy groups, industry and FDA. We gratefully acknowledge the contribution of another honoree, the Huntington"s Disease Society of America, in educating patients and caregivers about the appropriate use of Xenazine." Dr. Ashworth added, "The greatest validation of efforts in drug development derives from satisfying an unmet medical need. While Xenazine is not a cure, it can transform lives devastated by the uncontrollable movements symptomatic of an unremitting neurodegenerative disease." Biovail acquired North American rights to tetrabenazine through the September 2008 acquisition of Prestwick Pharmaceuticals, Inc. About Xenazine (tetrabenazine) Tetrabenazine is a highly selective and reversible centrally-acting dopamine depleting drug that works by inhibiting a molecule known as vesicular monoamine transporter 2 (VMAT2). Xenazine was approved by the FDA on August 15, 2008, for the treatment of chorea associated with Huntington"s disease, based on the results of a double-blind, placebo-controlled, Phase 3 study that found Xenazine significantly reduced patients" chorea burden, improved global outcome scores, and was generally safe and well tolerated. Additional post-marketing preclinical studies further elucidating the safety profile of the product are being conducted. Tetrabenazine has been available in Europe for more than 30 years and in Canada since 1996. Full prescribing information is available on the Investor Relations page of Biovail"s website at www.biovail.com. About Huntington"s Disease Affecting an estimated 25,000 Americans, Huntington"s disease is a devastating neurodegenerative disease that causes progressive movement disorders, cognitive dysfunction and behavioral changes and is ultimately a fatal condition. Chorea is the most common symptom, affecting approximately 90% of Huntington"s disease patients, and is characterized by excessive, involuntary and repetitive movements, which are the most visible and dangerous manifestations of Huntington"s disease and interfere with patients" abilities to perform activities of daily living, including dressing, bathing and caring for themselves. For more information about Huntington"s disease, please visit http://www.hdfoundation.org or http://www.hdsa.org. About NORD The National Organization for Rare Disorders (NORD) is a unique federation of voluntary health organizations dedicated to helping people with rare "orphan" diseases and assisting the organizations that serve them. NORD is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and service. Biovail Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009